Gene signatures for the prediction of response to Bacillus Calmette-Guérin immunotherapy in primary pT1 bladder cancers

Clinical Cancer Research

Volumn 16, Issue 7, 2010, Pages 2131-2137

  Kim, Yong June ^a,b   Ha, Yun Sok ^a   Kim, Seon Kyu ^a,b   Yoon, Hyung ^a,b   Lym, Min Su ^a,b   Kim, Min Ju ^a,b   Moon, Sung Kwon ^c   Choi, Yung Hyun ^d   Kim, Wun Jae ^a,b  

^a Chungbuk National University College of Medicine   (South Korea)

^b Chungbuk National University   (South Korea)

^c Chungju National University   (South Korea)

^d Dong Eui University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE;

ADULT; ARTICLE; BLADDER CANCER; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; IMMUNE RESPONSE; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REAL TIME POLYMERASE CHAIN REACTION;

AGED; CARCINOMA, TRANSITIONAL CELL; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; MYCOBACTERIUM BOVIS; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; URINARY BLADDER NEOPLASMS;

EID: 77950685757     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-3323     Document Type: Article

References (30)

1. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou- Redorta J. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008;54:303-314
2. Malmstrom PU, Sylvester RJ, Crawford DE, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur Urol 2009;56:247-256
3. Hall MC, Chang SS, Dalbagni G, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007;178:2314-2330
4. Saint F, Salomon L, Quintela R, et al. Do prognostic parameters of remission versus relapse after Bacillus Calmette-Guerin (BCG) immunotherapy exist? Analysis of a quarter century of literature. Eur Urol 2003;43:351-360
5. Fernandez-Gomez J, Solsona E, Unda M, et al. Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin: multivariate analysis of data from four randomized CUETO trials. Eur Urol 2008;53:992-1001.
6. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466-475
7. Decobert M, LaRue H, Harel F, Meyer F, Fradet Y, Lacombe L. Maintenance bacillus Calmette-Guerin in high-risk nonmuscle-invasive bladder cancer: How much is enough? Cancer 2008;113:710-716
8. Takayama H, Nishimura K, Tsujimura A, et al. Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation. J Urol 2009;181:1894-1900
9. Yutkin V, Pode D, Pikarsky E, Mandelboim O. The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin therapy: a pilot study. J Urol 2007;178:2660-2664
10. Ayari C, Larue H, Hovington H, et al. Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guerin immunotherapy. Eur Urol 2009;55:1386-1395
11. Alexandroff AB, Jackson AM, O'Donnell MA, James K. BCG immunotherapy of bladder cancer: 20 years on. Lancet 1999;353:1689-1694
12. Bubendorf L. High-throughput microarray technologies: from genomics to clinics. Eur Urol 2001;40:231-238
13. Quackenbush J. Microarray analysis and tumor classification. N Engl J Med 2006;354:2463-2472
14. Dyrskjot L, Thykjaer T, Kruhoffer M, et al. Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet 2003;33:90-96
15. Dyrskjot L, Zieger K, Kruhoffer M, et al. A molecular signature in superficial bladder carcinoma predicts clinical outcome. Clin Cancer Res 2005;11:4029-4036
16. Dyrskjot L, Zieger K, Real FX, et al. Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study. Clin Cancer Res 2007;13:3545-3551
17. Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 2006;24:778-789
18. Lee JS, Leem SH, Lee SY, et al. Expression signature of E2F1 and its associated genes predicts superficial-to-invasive progression of bladder tumors. J Clin Oncol. In press 2010.
19. Chen HY, Yu SL, Chen CH, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 2007;356:11-20.
20. Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 2004;350:1828-1837
21. Beer DG, Kardia SL, Huang CC, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002;8:816-824
22. Skrzypski M, Jassem E, Taron M, et al. Three-gene expression signature predicts survival in early-stage squamous cell carcinoma of the lung. Clin Cancer Res 2008;14:4794-4799
23. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-2826
24. Lee JS, Heo J, Libbrecht L, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 2006;12:410-416
25. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
26. Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007;446:153-158
27. Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006;314:268-274
28. Chuaqui RF, Bonner RF, Best CJ, et al. Post-analysis follow-up and validation of microarray experiments. Nat Genet 2002;32 Suppl:509-514
29. Michiels S, Koscielny S, Hill C. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 2005;365:488-492
30. Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 2005;5:713-725